Last reviewed · How we verify
Ycanth (CANTHARIDIN)
Cantharidin works by causing blistering and peeling of the skin, which helps to remove the Molluscum contagiosum virus.
At a glance
| Generic name | CANTHARIDIN |
|---|---|
| Sponsor | Verrica Pharms |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2023 |
Mechanism of action
The mechanism of action of cantharidin in the treatment of molluscum contagiosum is unknown.
Approved indications
- Infection caused by Molluscum contagiosum
Common side effects
- application site vesicles
- application site pain and pain
- application site pruritus and pruritus
- application site scab and scab
- application site erythema and erythema
- application site discoloration
- application site dryness
- application site edema
- application site erosion
Key clinical trials
- Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION) (NA)
- Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) (PHASE3)
- Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) (PHASE3)
- Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women (EARLY_PHASE1)
- Cantharidin and Occlusion in Verruca Epithelium (PHASE2)
- A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts (PHASE2)
- Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca (PHASE4)
- Cantharidin Application in Molluscum Patients-1 (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ycanth CI brief — competitive landscape report
- Ycanth updates RSS · CI watch RSS
- Verrica Pharms portfolio CI